# Pharmaceuticals — Drug development & impurities

> Move impurity and safety calls at the speed of a development program.

Drug programs run on tight timelines and heavy documentation: mutagenic-impurity control under ICH M7, safety assessment of intermediates and degradants, and read-across for compounds with thin data. ToxIndex runs those assessments reproducibly, so the paperwork keeps pace with the chemistry.

## Where pharma teams lose time

Impurity assessments, intermediate safety, and degradant characterization all demand a defensible (Q)SAR read and an audit trail, all on a schedule that does not wait. Manual assessment is both the bottleneck and the reproducibility risk.

ToxIndex runs these as versioned workflows over predictors and OECD read-across, so an assessment reproduces exactly when an auditor asks, and a reviewer can interrogate any call in plain language.

## Key facts
- **ICH M7** — impurity workflows, reproducible
- **100+** — tools, including mutagenicity models
- **Air-gapped** — deployment for sensitive pipelines

## What ToxIndex covers for pharma

### Mutagenic-impurity assessment
Run ICH M7 as a reproducible workflow: structural-alert profiling plus a second (Q)SAR read, classified and audit-trailed.

### Structure-based safety
Score intermediates and degradants from structure, with applicability-domain reads that show where the model is trustworthy.

### Read-across for thin data
The OECD QSAR Toolbox groups compounds and generates read-across the way regulators expect to review it.

### Keep data in your environment
Single-tenant and on-prem deployments keep chemical structures inside your own environment, air-gapped if you need it.

## Related platform tools
- [Flow](https://toxindex.com/platform/flow.md): Reproducible workflow engine
- [ToxJobs](https://toxindex.com/platform/toxjobs.md): Prediction toolkit
- [Sage](https://toxindex.com/platform/sage.md): Conversational answer engine

## Related solutions
- [ICH M7 impurity assessment](https://toxindex.com/solutions/ich-m7-mutagenic-impurities.md): Mutagenic impurities
- [New chemical assessment](https://toxindex.com/solutions/new-chemical-assessment.md): Novel substances
- [CROs](https://toxindex.com/solutions/cros.md): Contract research

## Frequently asked questions

**What pharma assessments does ToxIndex run?**

Mutagenic-impurity control under ICH M7, structure-based safety for intermediates and degradants, and read-across for compounds with thin data — each as a reproducible, audit-trailed workflow.

**Can we keep chemical structures inside our environment?**

Yes. Single-tenant and on-prem deployments keep structures inside your own environment, air-gapped if a pipeline requires it.

**How many tools are available?**

100+ deployed tools, including bacterial mutagenicity models for the second (Q)SAR read ICH M7 requires.

---
Canonical page: https://toxindex.com/solutions/pharmaceuticals